Eribulin mesylate + Eribulin mesylate + Rifampicin

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Tumor

Conditions

Tumor

Trial Timeline

Dec 1, 2009 → Jun 1, 2011

NCT ID

NCT03002493

About Eribulin mesylate + Eribulin mesylate + Rifampicin

Eribulin mesylate + Eribulin mesylate + Rifampicin is a phase 1 stage product being developed by Eisai for Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT03002493. Target conditions include Tumor.

What happened to similar drugs?

20 of 20 similar drugs in Tumor were approved

Approved (20) Terminated (3) Active (0)

✅PexidartinibDaiichi SankyoApproved

✅KRN23Kyowa KirinApproved

✅DurvalumabAstraZenecaApproved

✅aprepitant + Dexamethasone and Ondansetron during CE-treatmentMerckApproved

✅Everolimus (RAD001)NovartisApproved

✅Chromogranin ANovartisApproved

✅Pasireotide + DiazoxideNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03002493	Phase 1	Completed	Dec 1, 2009	Jun 1, 2011	Tumor

Competing Products

20 competing products in Tumor

See all competitors

Product	Company	Stage	Hype Score
ALG.APV-527	Alligator Bioscience AB	Phase 1/2	18
ATOR-1017	Alligator Bioscience AB	Phase 1	19
ATOR-1015	Alligator Bioscience AB	Phase 1	19
mRNA-4359	Moderna	Phase 2	0
mRNA-2752 + Durvalumab	AstraZeneca	Phase 1	29
mRNA-4106	Moderna	Phase 1	0
mRNA-4157 + Pembrolizumab + SoC Treatment	Merck	Phase 1	33
mRNA-2416	Moderna	Phase 2	0
E7050	Eisai	Phase 1	29
Fruquintinib	HUTCHMED	Phase 1	23
AFM24 + Atezolizumab 840 MG in 14 ML Injection	Affimed	Phase 1/2	14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)	Syros Pharmaceuticals	Phase 1	11
BBP-398 + sotorasib	BridgeBio Pharma	Phase 1	18
BBP-398 (Formerly known as IACS-15509)	BridgeBio Pharma	Phase 1	18
Cixutumumab	Eli Lilly	Phase 1	29
SON-1010	Sonnet BioTherapeutics	Phase 1	27
SON-1010	Sonnet BioTherapeutics	Phase 1/2	18
[203Pb]VMT-α-NET + [212Pb]VMT-α-NET	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT-α-NET	Perspective Therapeutics	Phase 1	27
[212Pb] VMT-α-NET	Perspective Therapeutics	Phase 1	27